Everlab, an AI health platform, announced a $10 million seed round led by Left Lane Capital to expand internationally, develop its AI healthtech, and build a product ecosystem for lifelong proactive care.
Chronic disease causes over 70% of deaths, yet most healthcare remains reactive. Everlab offers a tiered membership that includes diagnostics, doctor consultations, and health insights, providing personalized prevention at lower costs.
Members have access to services such as blood tests, MRIs, scans, and continuous monitoring, along with integrated support and prevention plans. Its proprietary AI platform analyzes health data, automates summaries, detects risks, and recommends actions, integrating with healthcare networks for real-time, longitudinal records. With tens of thousands on a waitlist and growing markets, Everlab aims for 20x growth this year.
The company has processed over 1 million biomarkers, with 25% yielding abnormal results and 2.5% resulting in life-changing findings. And members see improvements in modifiable biomarkers, proving the health impact.
How the funding will be used: The funding will help expand clinics, teams, and AI infrastructure to build a scalable global preventive healthcare system.
KEY QUOTES:
“We believe everyone deserves access to world-class preventive care. By combining AI with the knowledge of leading clinicians, we’ve built a new kind of health platform designed to deliver smarter, earlier care to millions.”
Marc Hermann, Founder and CEO of Everlab
“Preventive care has always been a medical ideal but rarely a commercial reality. Everlab has built a product and model that makes it scalable, combining clinical depth with software leverage and operational precision. We’re excited to support them as they build a category-defining platform.”
Laura Sillman, Principal at Left Lane Capital
